Eli Lilly in Talks to Acquire Psychedelic Drugmaker AtaiBeckley, Report Says

Pharmaceutical giant Eli Lilly & Co. is in talks to acquire AtaiBeckley, a developer of psychedelic-based therapies, in a deal that could be announced as soon as this week. The potential acquisition, reported by Bloomberg News citing people familiar with the matter, would mark a significant expansion of Lilly's neuroscience pipeline into novel treatments for psychiatric disorders.

Reported Deal Structure

According to the report, Indianapolis-based Eli Lilly is negotiating a takeover at a premium to AtaiBeckley’s market value, which has climbed to approximately $2 billion. The valuation follows a period of strong performance for AtaiBeckley's stock, which has more than doubled over the past year.

The sources indicated that while discussions are advanced, they remain confidential, and there is no certainty that a final agreement will be reached.

Strategic Rationale and Market Impact

A successful acquisition would broaden Lilly’s portfolio with a platform of rapid-acting, psychedelic-based therapies. Analysts at BMO Capital Markets noted that the move would push Lilly further into treatments for treatment-resistant depression (TRD) and other difficult-to-manage psychiatric conditions.

Ad

This potential deal reflects growing pharmaceutical industry interest in psychedelic medicines, spurred by increasing regulatory support and the commercial success of products like Johnson & Johnson’s Spravato. For Lilly, it would add a "potentially differentiated late-stage neuropsychiatric asset," the BMO analysts added.

AtaiBeckley's Pipeline

AtaiBeckley's lead candidate is BPL-003, a fast-acting psychedelic nasal spray that has shown encouraging results in mid-stage trials for treatment-resistant depression. The U.S. Food and Drug Administration has granted the candidate its Breakthrough Therapy designation, which is intended to expedite the development and review of promising drugs for serious conditions.

Beyond BPL-003, AtaiBeckley's pipeline includes other potential therapies such as VLS-01 for TRD and EMP-01 for social anxiety disorder, offering Lilly additional pipeline optionality in the mental health space.